Solasodine

SKU: orb1222781

Description

Solasodine is a potentially useful precursor for steroidal compounds and hormones with anticonvulsant and central nervous system depressant activities.(In Vitro):Solasodine (90 μM; 2 days) treatment displays significant sprouting in P19 cells. Solasodine induces strong expression of the different neuronal markers studied, including βIII-tubulin, synaptophysin, MAP2, ChAT, and neuroblast marker doublecortin. Solasodine induces the differentiation of P19 cells, essentially towards the neuronal pathway. Solasodine induce apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins.(In Vivo):Solasodine (25-100 mg/kg; intraperitoneal injection; once) treatment significantly delays latency of hind limb tonic extensor (HLTE) phase in the PCT-induced convulsions. And significantly potentiates Thiopental-provoked sleep in a dose-dependent manner. Solasodine has anticonvulsant and CNS depressant activities.Solasodine (375 μM; i.c.v.; for 2 weeks) treatment results a significant increase in bromodeoxyuridine uptake by cells of the ependymal layer, subventricular zone, and cortex that co-localized with doublecortin immunostaining. Solasodine treatment in rats results in a dramatic increase in expression of the cholesterol- and drug-binding translocator protein in ependymal cells.

Key Properties

• CAS Number: 126-17-0
• MW: 413.65
• Purity: >98% (HPLC)
• Formula: C₂₇H₄₃NO₂
• SMILES: C[C@]12CC[C@@H](CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@H]1[C@@H]2[C@@H]([C@@]2(CC[C@H](CN2)C)O1)C)O
• Target: CXCR
• Solubility: DMSO : 2.6 mg/mL 6.29 mM; H2O : < 0.1 mg/mL

Bioactivity

• In Vivo:
  Solasodine (25-100 mg/kg; intraperitoneal injection; once) treatment significantly delays latency of hind limb tonic extensor (HLTE) phase in the PCT-induced convulsions. And significantly potentiates Thiopental-provoked sleep in a dose-dependent manner. Solasodine has anticonvulsant and CNS depressant activities. Solasodine (375 μM; i. c. v. ; for 2 weeks) treatment results a significant increase in bromodeoxyuridine uptake by cells of the ependymal layer, subventricular zone, and cortex that co-localized with doublecortin immunostaining. Solasodine treatment in rats results in a dramatic increase in expression of the cholesterol-and drug-binding translocator protein in ependymal cells. Animal model: Swiss albino mice (18-25 g) treated with Picrotoxin (PCT) or Thiopental. Dosage: 25 mg/kg, 50 mg/kg and 100 mg/kg. Administration: Intraperitoneal injection; once. Result: Significantly delayed latency of hind limb tonic extensor (HLTE) phase in the PCT-induced convulsions. And significantly potentiated Thiopental-provoked sleep in a dose-dependent manner.
  Read more...
• In Vitro:
  Solasodine (90 μM; 2 days) treatment displays significant sprouting in P19 cells. Solasodine induces strong expression of the different neuronal markers studied, including βIII-tubulin, synaptophysin, MAP2, ChAT, and neuroblast marker doublecortin. Solasodine induces the differentiation of P19 cells, essentially towards the neuronal pathway. Solasodine induce apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Purapuridine | Solancarpidine | Solasodin

Quick Database Links

Gene Symbol

CXCR